ପିରଫେନିଡନ

ପିରଫେନିଡନ
Clinical data
Trade names	Esbriet, Pirespa, Etuary, others
AHFS/Drugs.com	monograph
MedlinePlus	a615008
data	EU EMA: yes; US DailyMed: Pirfenidone;
Routes of; administration	By mouth
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Pharmacokinetic data
Protein binding	50–58%
Metabolism	Hepatic (70–80% CYP1A2-mediated; minor contributions from CYP2C9, CYP2C19, CYP2D6 and CYP2E1)
Elimination half-life	2.4 hours
Excretion	Urine (80%)
Identifiers
	IUPAC name 5-Methyl-1-phenylpyridin-2-one;
ECHA InfoCard	100.150.129
Chemical and physical data
Formula	C12H11NO
Molar mass	୧୮୫.୨୩ g·mol−1
3D model (JSmol)	Interactive image;
Solubility in water	10 mg/mL (20 °C)
	SMILES CC1=CN(C(=O)C=C1)C2=CC=CC=C2;
	InChI InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3; Key:ISWRGOKTTBVCFA-UHFFFAOYSA-N;
(verify)

ପିରଫେନିଡନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ପିରେସ୍ପା, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଇଡିଓପାଥିକ୍ ଫୁସଫୁସ ଫାଇବ୍ରୋସିସ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଏହା ସାମାନ୍ୟରୁ ମଧ୍ୟମ ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଇ, ରାସ, ଥକାପଣ, ବୁକୁଜ୍ୱାଳା, ମୁଣ୍ଡବିନ୍ଧା ଏବଂ ଆତପଦାହ ହୋଇପାରେ ।^[୨] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯକୃତ ସମସ୍ୟା ହୋଇପାରେ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ଦେଲେ ସୁରକ୍ଷା ସ୍ପଷ୍ଟ ନୁହେଁ ।^[୫] ଏହା କିପରି କାମ କରେ ତାହା ସମ୍ପୂର୍ଣ୍ଣ ସ୍ପଷ୍ଟ ନୁହେଁ, ତଥାପି ଏହା ଫାଇବ୍ରୋବ୍ଲାଷ୍ଟର ଉତ୍ପାଦନକୁ ହ୍ରାସ କରିଥାଏ ।^[୨]

୨୦୧୧ ମସିହାର ୟୁରୋପରେ ଏବଂ ୨୦୧୪ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ପିରଫେନିଡନ ବ୍ୟବହାର ହୋଇଥିଲା।^[୨]^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ୪ ସପ୍ତାହର ଔଷଧ ଖର୍ଚ୍ଚ ୨୦୨୧ ମସିହାର ପ୍ରାୟ ୨୦୦୦ପାଉଣ୍ଡ ଥିଲା ।^[୩]

ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ସେହି ପରିମାଣର ଔଷଧ ଖର୍ଚ୍ଚ ପ୍ରାୟ ୯୯୦୦ ଡଲାର ଥିଲା ।^[୬]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ "Esbriet 267 mg hard capsules". electronic Medicines Compendium. Intermune UK & I Ltd. 3 January 2014. Archived from the original on 12 October 2013. Retrieved 6 March 2014.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ "Esbriet". Archived from the original on 24 November 2020. Retrieved 28 October 2021.
↑ ^୩.୦ ^୩.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 314. ISBN 978-0857114105.
↑ ^୪.୦ ^୪.୧ "Pirfenidone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 June 2020. Retrieved 28 October 2021.
↑ "Pirfenidone (Esbriet) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 28 October 2021.
↑ "Esbriet Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 January 2021. Retrieved 28 October 2021.

[EMC-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ "Esbriet 267 mg hard capsules". electronic Medicines Compendium. Intermune UK & I Ltd. 3 January 2014. Archived from the original on 12 October 2013. Retrieved 6 March 2014.

[EPAR2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ "Esbriet". Archived from the original on 24 November 2020. Retrieved 28 October 2021.

[BNF81-3] ୩.୦ ^୩.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 314. ISBN 978-0857114105.

[AHFS2021-4] ୪.୦ ^୪.୧ "Pirfenidone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 June 2020. Retrieved 28 October 2021.

[5] "Pirfenidone (Esbriet) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 28 October 2021.

[6] "Esbriet Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 January 2021. Retrieved 28 October 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]